

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-141) TALQUETAMAB
PRONUNCIATION tal kwe' ta mab
THERAPEUTIC CLAIM Treatment of multiple myeloma

CHEMICAL NAMES

1. Immunoglobulin G4 [233-proline,239-alanine,240-alanine,410-leucine,414-lysine], anti-(human CD3 antigen) (human monoclonal JNJ-63483043 γ 4-chain), disulfide with human monoclonal JNJ-63483043 λ -chain, (231→224'), (234→227')-bis(disulfide) with immunoglobulin G4 [226-proline,232-alanine,233-alanine] anti-(human G protein-coupled receptor GPRC5D) (human monoclonal JNJ-64386972 γ 4-chain) disulfide with human monoclonal JNJ-64386972 λ -chain (Source: CAS)
2. Immunoglobulin G4-kappa/G4-lambda, anti-[*Homo sapiens* GPRC5D (G protein-coupled receptor class C group 5 member D)], and anti-[*Homo sapiens* CD3E (CD3 epsilon, Leu-4)], humanized and chimeric monoclonal antibody; bispecific gamma4 heavy chain humanized anti-GPRC5D (1-445) [VH (*Homo sapiens* IGHV1-18*01 (89.8%) -(IGHD) -IGHJ4*01 (92.9%)) [8.8.11] (1-118) - *Homo sapiens* IGHG4*01 (CH1 (119-216), hinge 1-12 S10>P (226) (217-228), CH2 F1.3>A (232), L1.2>A (233) (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-214')-disulfide with kappa light chain humanized anti-GPRC5D (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-17*02 (85.3%) -IGKJ2*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; gamma4 heavy chain chimeric anti-CD3E (1-452) [VH (*Mus musculus* IGHV10-1*02 (89.8%)/*Homo sapiens* IGHV3-72*01 (88.0%) -(IGHD) -IGHJ6*01 (90.9%)) [8.10.16] (1-125) -*Homo sapiens* IGHG4*01 (CH1 (126-223), hinge 1-12 S10>P (233) (224-235), CH2 F1.3>A (239), L1.2>A (240) (236-345), CH3 F85.1>L (410), R88>K (414) (346-450), CHS (451-452)) (126-452)], (139-214')-disulfide with lambda light chain humanized anti-CD3E (1'-215') [V-LAMBDA (*Homo sapiens* IGLV7-43*01 (81.9%) -IGLJ3*02 (100%)) [9.3.9] (1'-109') -*Homo sapiens* IGLC2*01 (100%) (110'-215')]; dimer (224-231":227-234")-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-K1 cell line, glycoform alfa (Source: WHO pINN list 121)

STRUCTURAL FORMULA

Heavy chain X (Anti- Anti-GPRC5D)

QVQLVQSGAE	VKKPGASVKV	SCKASGYSFT	GYTMNWVRQA	PGQGLEWMGL	50
INPYNSDTNY	AQKLQGRVTM	TTDTSTSTAY	MELRSLRSDD	TAVYYCARVA	100
LRVALDYWGQ	GTLVTVSSAS	TKGPSVFPLA	PCSRSTSEST	AALGCLVKDY	150
FPPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	SSSLGTKTYT	200
CNVDHKPSNT	KVDKRVESKY	GPPCPPCPAP	EAAGGPSVFL	FPPKPKDTLM	250
ISRTPEVTCV	VVDVSEQEDPE	VQFNWYVDGV	EVHNAKTKPR	EEQFNSTYRV	300
VSVLTVLHQD	WLNKEYKCK	VSNKGLPSSI	EKTISKAKGQ	PREPQVYTLP	350
PSQEEMTKNQ	VSLTCLVKGF	YPSDIAVEWE	SNGQPENNYK	TTPPVLDSDG	400
SFFLYSRLTV	DKSRWQEGNV	FSCSVMEAL	HNHYTQKSLS	LSLGK	445

Light chain X' (Anti-GPRC5D)

DIQMTQSPSS	LSASVGDRTV	ITCKASQNV	THVGWYQQK	GKAPKRLIYS	50'
ASYRYSQVPS	RFSGSGSGTE	FLLTISNLQP	EDFATYYCQQ	YNRYPYTFGQ	100'
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Heavy chain X'' (Anti-CD3)

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFN	TYAMNWVRQA	PGKGLEWVAR	50
IRSKYNNYAT	YYAASVKGRF	TISRDDSKNS	LYLQMNSLKT	EDTAVYYCAR	100
HGNFGNSYVS	WFAYWGQGT	VTVSSASTKG	PSVFPPLPCS	RSTSESTAAL	150
GCLVKDYFPE	PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVTVTPSSS	200
LGTKTYTCNV	DHKPSNTKVD	KRVESKYGPP	CPPCPAPEAA	GGPSVFLFPP	250
KPKDTLMISR	TPEVTCVVVD	VSQEDPEVQF	NWYVDGVEVH	NAKTKPREEQ	300
FNSTYRVVSV	LTVLHQDWLN	GKEYKCKVSN	KGLPSSIEKT	ISKAKGQPRE	350
PQVYTLPPSQ	EEMTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QPENNYKTP	400
PVLDSGDSFL	LYSKLTVDKS	RWQEGNVFSC	SVMHEALHNN	YTQKSLSLSL	450
GK					452

Light chain X''' (Anti-CD3)

QTVVTEPESL	TVSPGGTVTL	TCRSSTGAVT	TSNYANWVQQ	KPGQAPRGLI	50'
GGTNKRAPGT	PARFSGSLLG	GKAALTLSGV	QPEDEAEYYC	ALWYSNLWVF	100'
GGGTKLTVLG	QPKAAPSVTL	FPPSSEELQA	NKATLVCLIS	DFYPGAVTVA	150'
WKADSSPVKA	GVETTPPSKQ	SNNKYAASSY	LSLTPEQWKS	HRSYSCQVTH	200'
EGSTVEKTVA	PTECS				215'

Disulfide bridges

22-96	22''-98'	23'-88'	22'''-90'''	132-214'	139''-214'''	134'-194'	137'''-196''
145-201	152''-208''	224-231'	224-234''	259-319	266''-326''	365-423	372''-430''

Glycosylation sites (N)

295	302''
-----	-------

MOLECULAR FORMULA C₆₄₁₀H₉₉₃₈N₁₇₁₆O₂₀₀₆S₄₅

MOLECULAR WEIGHT 144.5 kDa

TRADEMARK None as yet

SPONSOR Johnson & Johnson

CODE DESIGNATIONS JNJ-64407564

CAS REGISTRY NUMBER 2226212-40-2

UNII 4W3KFI3TN3

WHO NUMBER 11173

gbk